Literature DB >> 25696698

Percutaneous transluminal septal myocardial ablation in hypertrophic cardiomyopathy.

C van der Lee, D P Foley, W B Vletter, F J Ten Cate, M J M Kofflard.   

Abstract

BACKGROUND: Percutaneous transluminal septal myocardial ablation (PTSMA) is a new interventional technique to treat patients with hypertrophic cardiomyopathy.
METHODS: Small doses of ethanol 96% were injected into a targeted septal artery causing a chemical myocardial infarction. Three patients were evaluated, including a follow-up of three months.
RESULTS: There were no complications during the procedure LVOT gradient was reduced from 120±140 mmHg. At follow-up, all three patients showed improvement in validity.
CONCLUSION: The method requires an echocardiographic contrast determination of the myocardium at risk for ethanol treatment, in addition to haemodynamic monitoring.

Entities:  

Keywords:  PTSMA; echocontrast; hypertropic cardiomyopathy

Year:  2001        PMID: 25696698      PMCID: PMC2499591     

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  6 in total

1.  Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy.

Authors:  F H Gietzen; C J Leuner; U Raute-Kreinsen; A Dellmann; J Hegselmann; C Strunk-Mueller; H J Kuhn
Journal:  Eur Heart J       Date:  1999-09       Impact factor: 29.983

Review 2.  Alcohol septal ablation in hypertrophic obstructive cardiomyopathy: the need for a registry.

Authors:  W H Spencer; R Roberts
Journal:  Circulation       Date:  2000-08-08       Impact factor: 29.690

3.  Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy.

Authors:  N M Lakkis; S F Nagueh; N S Kleiman; D Killip; Z X He; M S Verani; R Roberts; W H Spencer
Journal:  Circulation       Date:  1998-10-27       Impact factor: 29.690

Review 4.  Hypertrophic cardiomyopathy.

Authors:  B J Maron
Journal:  Lancet       Date:  1997-07-12       Impact factor: 79.321

Review 5.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

Authors:  B J Maron; R O Bonow; R O Cannon; M B Leon; S E Epstein
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

6.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy.

Authors:  U Sigwart
Journal:  Lancet       Date:  1995-07-22       Impact factor: 79.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.